Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Cystic Fibrosis -- No Longer Just a Disease of Pediatric Medicine

Cystic fibrosis (CF) is an autosomal recessive disease caused by genetic mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. At the cellular level, the CFTR protein is an...
CME credit is no longer available for this conference.

Course Authors

Arindam Singha, M.D., and Stephen E. Kirkby, M.D.

Dr. Singha is Fellow, Pulmonary & Critical Care Medicine, The Ohio State University Medical Center, and Dr. Kirkby is Associate Professor, Pulmonary & Critical Care Medicine, The Ohio State University Medical Center and Nationwide Children’s Hospital, Columbus, OH.

Within the past 12 months, Drs. Singha and Kirkby have nothing to disclose relevant to this activity.

Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose relevant to this activity.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Discuss the basic pathogenesis of cystic fibrosis, and recent trends in survival and outcome;

  • List the diagnostic criteria including CFTR mutation;

  • Describe the organ specific manifestation of disease;

  • Manage both acute exacerbation and chronic disease including pharmacologic and non pharmacologic therapies;

  • Evaluate and apply the new and emerging disease-modifying therapies for CF.

 

TERMS AND CONDITIONS

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity

Courses You Might Like

Asthma Management: A Multi-Faceted Approach

This presentation may include discussion of commercial products and services. Based on national survey data, 24.6 million people report a diagnosis of asthma in the United States, representing approximately 7.7% of adults and 9.6% of children. Certain populations including women, blacks and the poor are disproportionately affected. The direct and indirect costs related to adult asthma care in the United States were estimated to
Authors: Cathy G. Benninger, R.N., M.S., C.N.P., and Jennifer W. McCallister, M.D.
Estimated Time: 1 Hour
More

Idiopathic Pulmonary Fibrosis

A competitive, interactive game format that will discuss the essentials of the management of idiopathic pulmonary fibrosis. This presentation may include discussion of commercial products and services. Table 1. Clinical Strategies for the Improvement of Asthma Control. Identify and manage co-morbid conditions which affect asthma control Source: based on the four key components of asthma management as outlined in the current National Heart, Lung, and Blood Institute (NHLBI) National Asthma Education and
Authors: Ganesh Raghu, M.D., and Samuel G. Rayner, M.D.
Estimated Time: 2 Hours
More

The Role of Matrix Metalloproteinases (MMPs) in COPD

Though the pathophysiology of chronic bronchitis and emphysema is distinct, there are common processes that are linked to their development. For one, both syndromes are caused by chronic exposure to cigarette smoke, which generates a robust inflammatory response in the lung that results in a marked increase in proteases within the lung. Animal and human studies indicate that the presence of these proteases is a critical factor in the development of these diseases. In chronic bronchitis,
Authors: Robert Foronjy, M.D., and Jeanine D'Armiento, M.D., Ph.D.
Estimated Time: 1 Hour
More

Acute Lung Injury and the Acute Respiratory Distress Syndrome

Acute lung injury (ALI) and its more severe manifestation, the acute respiratory distress syndrome (ARDS), are among the most common causes of acute hypoxemic respiratory failure in the intensive care unit (ICU). ALI complicates many medical and surgical conditions and represents a complex pathophysiologic sequela to a variety of different pulmonary and extrapulmonary insults. Initially described in the 1960s, ARDS is characterized by refractory hypoxemia, diffuse pulmonary infiltrates and decreased lung compliance. ALI and ARDS both represent
Authors: Chirag V. Shah, M.D., M.S., and Jason D. Christie, M.D., M.S.
Estimated Time: 1 Hour
More

The Diagnosis and Management of Venous Thromboembolism

The differential diagnosis for acute PE is broad and includes a number of cardiopulmonary diseases and, occasionally, intra-abdominal processes may be mimicked by PE. Hypoxemia is extremely common but not always present in acute PE. The diagnostic utility of plasma measurements of circulating D-dimer (a specific derivative of cross-linked fibrin) has been extensively evaluated in patients with PE. A number of D-dimer assays are available, and the sensitivity and specificity of these assays vary. A positive D-dimer test means that
Authors: Victor F. Tapson, M.D.
Estimated Time: 1 Hour
More

Idiopathic Pulmonary Fibrosis

Drs. Collard and King will discuss the unapproved and investigational use of cyclophosphamide, azathioprine, acetylcysteine, interferon gamma 1b, bosentan, pirfenidone and warfarin for the treatment of idiopathic pulmonary fibrosis. Case Report A 65-year-old man presents with shortness of breath and cough. Over the last six months he has had increasing breathlessness with exertion. He has a dry cough that is worse with exertion. He is a
Authors: Harold R. Collard, M.D., and Talmadge E. King, Jr., M.D.
Estimated Time: 1 Hour
More